Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Mesothelioma, Malignant 2Lymphoma, T-Cell 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 42Rituximab 40Vincristine 31Doxorubicin 29Prednisone 28Etoposide 27Filgrastim 22Peripheral Blood Stem Cell Transplantation 16Radiotherapy 12Ifosfamide 12Cytarabine 12Magnetic Resonance Spectroscopy 10Methotrexate 9Lenalidomide 8Cyclosporine 8Bortezomib 8fludarabine phosphate 7Vorinostat 7Specimen Handling 7Cisplatin 7Carboplatin 7tanespimycin 6ibrutinib 6Melphalan 6Gemcitabine 6Biopsy 6oblimersen 5alvocidib 5aldesleukin 5Oxaliplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large B-Cell, Diffuse × Depsipeptides × Clear all
NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡